NAV

2-Ribofuranosyl-3-Iodo-2,3-Dihydro-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine

Identification

Generic Name
2-Ribofuranosyl-3-Iodo-2,3-Dihydro-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
DrugBank Accession Number
DB02416
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 395.1537
Monoisotopic: 395.009047381
Chemical Formula
C10H14IN5O4
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyrazolo[3,4-d]pyrimidine glycosides. These are nucleosides or derivatives thereof that consist of a pyazolo[3,2-d]pyrimidine ring system that is N-glycosidically linked to a ribose or deoxyribose. They bear the sugar moiety on the pyrimidine part of the molecule.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Pyrazolo[3,4-d]pyrimidine glycosides
Sub Class
Not Available
Direct Parent
Pyrazolo[3,4-d]pyrimidine glycosides
Alternative Parents
Glycosylamines / Pentoses / Pyrazolopyrimidines / Aminopyrimidines and derivatives / Imidolactams / Tetrahydrofurans / Pyrazoles / Heteroaromatic compounds / Secondary alcohols / Alkylhydrazines
show 8 more
Substituents
Alcohol / Alkyl halide / Alkyl iodide / Alkylhydrazine / Amine / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Glycosyl compound / Heteroaromatic compound
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organoiodine compound, N-glycosyl compound, pyrazolopyrimidine (CHEBI:45448)
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
IPMOTTQXPAXTMS-CKVFBBIQSA-N
InChI
InChI=1S/C10H14IN5O4/c11-7-4-8(12)13-2-14-9(4)16(15-7)10-6(19)5(18)3(1-17)20-10/h2-3,5-7,10,15,17-19H,1H2,(H2,12,13,14)/t3-,5-,6-,7+,10-/m1/s1
IUPAC Name
(2R,3R,4S,5R)-2-[(3R)-4-amino-3-iodo-1H,2H,3H-pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
SMILES
[H][C@]1(I)NN(C2=NC=NC(N)=C12)[C@]1([H])O[C@]([H])(CO)[C@@]([H])(O)[C@@]1([H])O

References

General References
Not Available
PubChem Compound
17754151
PubChem Substance
46505819
ChemSpider
16744184
ChEBI
45448
ZINC
ZINC000033821509
PDBe Ligand
RPP
PDB Entries
1lij

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.86 mg/mLALOGPS
logP-1.4ALOGPS
logP-0.64Chemaxon
logS-1.9ALOGPS
pKa (Strongest Acidic)12.54Chemaxon
pKa (Strongest Basic)7.83Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count9Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area136.99 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity98.65 m3·mol-1Chemaxon
Polarizability30.17 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.7965
Blood Brain Barrier+0.8794
Caco-2 permeable-0.7242
P-glycoprotein substrateNon-substrate0.7428
P-glycoprotein inhibitor INon-inhibitor0.9512
P-glycoprotein inhibitor IINon-inhibitor0.9826
Renal organic cation transporterNon-inhibitor0.9501
CYP450 2C9 substrateNon-substrate0.866
CYP450 2D6 substrateNon-substrate0.8293
CYP450 3A4 substrateNon-substrate0.5343
CYP450 1A2 substrateNon-inhibitor0.7935
CYP450 2C9 inhibitorNon-inhibitor0.8521
CYP450 2D6 inhibitorNon-inhibitor0.8921
CYP450 2C19 inhibitorNon-inhibitor0.8458
CYP450 3A4 inhibitorNon-inhibitor0.7784
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8547
Ames testNon AMES toxic0.6905
CarcinogenicityNon-carcinogens0.872
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2638 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9793
hERG inhibition (predictor II)Non-inhibitor0.8519
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0adi-9448000000-c2f50b266ce45d6d2dc6
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0091000000-f76de2224a55a9349032
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-01q9-0940000000-148706b0a0b47cb53241
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0090000000-8b083611ccec3a7401c3
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0920000000-ffc1d360d5597530ad9f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dj-0191000000-c636ae1b1537d98a134d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-005j-0970000000-6732cda01e4d5c6d5015
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-163.96632
predicted
DeepCCS 1.0 (2019)
[M+H]+166.36191
predicted
DeepCCS 1.0 (2019)
[M+Na]+172.85515
predicted
DeepCCS 1.0 (2019)

Drug created at June 13, 2005 13:24 / Updated at July 02, 2020 13:16